Takamatsu et al. proposed that inhibiting p53 aggregation through various methods, that is, reducing the evolutionary ability of p53 to nuclear stress, may enhance the effectiveness of cancer treatment and reduce cancer recurrence [48]. The gene discussed is TP53; the disease is cancer.